Amicus Therapeutics, Inc. (FOLD)
-NasdaqGM | Prev Close: | 2.52 |
|---|
| Open: | N/A |
|---|
| Bid: | 1.89 x 200 |
|---|
| Ask: | 2.78 x 300 |
|---|
| 1y Target Est: | 4.70 |
|---|
| Beta: | 1.93 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.30 - 6.89 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 414,461 |
|---|
| Market Cap: | 124.82M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.10 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AMICUS THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Tue, Jun 18)
- Stocks Pare Gains on Speculation of Fed Taperingat TheStreet(Mon, Jun 17)
- Amicus Therapeutics' CEO Presents at Fabry Monotherapy Strategic Update Conference (Transcript)at Seeking Alpha(Mon, Jun 17)
- Analysts: Yahoo Won’t Reach Google Deal and 3 More Research Notes to Exploreat Wall St. Cheat Sheet(Mon, Jun 17)
- Amicus Falls as Fabry Disease Drug Trials Need More Timeat Bloomberg(Mon, Jun 17)
- Amicus falls to annual low on Fabry drug rulingAP(Mon, Jun 17)
- Tesla Rides a New Upgrade, BioScrip Buys CarePoint, and 3 More Hot Stocksat Wall St. Cheat Sheet(Mon, Jun 17)
- Amicus Delays U.S. Approval Filing for Fabry Disease Drugat TheStreet(Mon, Jun 17)
- InPlay: Amicus Therapeutics to host conference call today at 8:00 a.m. ET to discuss regulatory strategy for Migalastat HCl Monotherapy for Fabry DiseaseBriefing.com(Mon, Jun 17)
- Amicus Therapeutics to Host Conference Call Today at 8:00 a.m. ET to Discuss Regulatory Strategy for Migalastat HCl Monotherapy for Fabry DiseaseGlobeNewswire(Mon, Jun 17)
- AMICUS THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Mon, Jun 17)
- These 2 Biotechs May Surprise Investors, Says Janney Analyst Kimberly Leeat Seeking Alpha(Wed, Jun 12)
- Amicus Therapeutics to Present at Jefferies 2013 Global Healthcare ConferenceGlobeNewswire(Thu, May 30)
- AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhiEDGAR Online(Wed, May 22)
- Amicus Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Tue, May 21)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 11.73 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.40 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.35 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones.
View More